Meeder Asset Management’s Pacific Biosciences PACB Stock Holding History

Meeder Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-61	Closed	-$1K	–	1992
2021 Q3	$1K	Sell	61 -2,255	-97%	-$66.8K	﹤0.01%	2352
2021 Q2	$81K	Sell	2,316 -4,238	-65%	-$123K	﹤0.01%	966
2021 Q1	$219K	Buy	+6,554	New	+$229K	0.01%	702
2017 Q2	–	Sell	-83	Closed	–	–	1813
2017 Q1	$0	Buy	+83	New	+$406	﹤0.01%	1714
2016 Q3	–	Sell	-176	Closed	-$1K	–	897
2016 Q2	$1K	Buy	+176	New	+$1.61K	﹤0.01%	860

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meeder Asset Management's PACB Position: Q4 2021 in Review

Meeder Asset Management sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 61 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in PACB in Q2 2016 and held it in 5 quarters. The position peaked at $219K in Q1 2021. 256 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

Meeder Asset Management reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 61 Pacific Biosciences shares in Q4 2021, an estimated $1K.
Meeder Asset Management first reported a position in Pacific Biosciences in Q2 2016 and held it in 5 quarters.
Meeder Asset Management's Pacific Biosciences position peaked at $219K in Q1 2021.
256 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.